Barb73 Posted June 3, 2008 Share Posted June 3, 2008 Article: . . . . . . . . . PARIS (Thomson Financial) - French biotech company Transgene said the primary endpoint has been achieved in a Phase IIb trial evaluating its therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to first line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Results of the trial will be presented today at the 2008 annual meeting of the American Society of Clinical Oncology in Chicago. 'These results clearly warrant pursuing development into a Phase III program and we will be seeking to establish a partnership in order to complete the last stages of clinical development and bring TG4010 to the market,' Philippe Archinard, Transgene CEO, said in a statement. The Phase IIb trial involved 148 patients and was conducted in 27 centres located in France, Poland, Germany, and Hungary. The trial met its primary endpoint, with a progression-free survival (PFS) at six months of 44 percent (33 out of 74 patients) in the experimental arm. In the control arm, PFS at six months was 35 percent (26 of 74 patients), the company said. Additionally, the response rate is substantially higher for the combination of TG4010 with chemotherapy compared to the chemotherapy alone, it said. TG4010 (MVA-MUC1-IL2) uses the Modified Vaccinia Ankara virus vector. . . . . . . . . . (FORBES, Thomson Financial News, June 2, 2008) Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.